|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600117484 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-26 08:27:16 |
|
注册时间: Date of Registration: |
2026-01-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
微脉冲激光小梁成形术治疗开角型青光眼疗效和安全性的研究 |
|
Public title: |
A Study on the Efficacy and Safety of Micropulse Laser Trabeculoplasty in the Treatment of Open-Angle Glaucoma |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
微脉冲激光小梁成形术治疗开角型青光眼疗效和安全性的研究 |
|
Scientific title: |
A Study on the Efficacy and Safety of Micropulse Laser Trabeculoplasty in the Treatment of Open-Angle Glaucoma |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
谢佩玲 |
研究负责人: |
谢佩玲 |
|
Applicant: |
Peiling Xie |
Study leader: |
Peiling Xie |
|
申请注册联系人电话: Applicant telephone: |
+86 135 1692 6849 |
研究负责人电话: Study leader's telephone: |
+86 135 1692 6849 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xpl09021010306@163.com |
研究负责人电子邮件: Study leader's E-mail: |
xpl09021010306@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国浙江省金华市婺城区人民东路365号 |
研究负责人通讯地址: |
中国浙江省金华市婺城区人民东路365号 |
|
Applicant address: |
No. 365, Renmin East Road, Wucheng District, Jinhua, Zhejiang, China |
Study leader's address: |
No. 365, Renmin East Road, Wucheng District, Jinhua, Zhejiang, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
浙江大学医学院附属金华医院 |
||
|
Applicant's institution: |
Affiliated Jinhua Hospital, Zhejiang University School of Medicine |
||
|
研究负责人所在单位: |
浙江大学医学院附属金华医院 |
||
|
Affiliation of the Leader: |
Affiliated Jinhua Hospital, Zhejiang University School of Medicine |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(研) 2025-伦理审查-314 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
金华市中心医院医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Review Committee of Jinhua Central Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-19 00:00:00 |
||
|
伦理委员会联系人: |
吴渝骐鸣 |
||
|
Contact Name of the ethic committee: |
Yuqiming Wu |
||
|
伦理委员会联系地址: |
中国浙江省金华市婺城区人民东路365号 |
||
|
Contact Address of the ethic committee: |
No. 365, Renmin East Road, Wucheng District, Jinhua, Zhejiang, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 187 5790 9715 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
浙江大学医学院附属金华医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Jinhua Hospital, Zhejiang University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国浙江省金华市婺城区人民东路365号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 365, Renmin East Road, Wucheng District, Jinhua, Zhejiang, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
Target disease: |
Open-Angle Glaucoma |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本项目拟通过对不同类型的开角型青光眼进行MLT治疗,通过观察眼压、角膜内皮镜、眼前段OCT以及视盘OCT和电脑视野等检查结果,评估MLT在开角型青光眼中的降眼压疗效以及安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to evaluate the efficacy and safety of Micropulse Laser Trabeculoplasty (MLT) in reducing intraocular pressure among various subtypes of open-angle glaucoma. Assessments will be conducted through comprehensive examinations including tonometry, corneal endothelial microscopy, anterior segment optical coherence tomography (OCT), optic disc OCT, and computerized perimetry. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)原发性开角型青光眼; 2)正常眼压性青光眼; 3)高眼压症; 4)继发性青光眼,房角开放,如玻切术后眼压升高,激素性青光眼; 5)患者自愿接受微脉冲激光小梁成形术治疗,并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1) Primary open-angle glaucoma; 2) Normal-tension glaucoma; 3) Ocular hypertension; 4) Secondary open-angle glaucoma, such as elevated intraocular pressure following vitrectomy or steroid-induced glaucoma; 5) Patients voluntarily underwent micropulse laser trabeculoplasty and provided written informed consent. |
||||||||||||||||||||||
|
排除标准: |
1)任何象限出现房角关闭或房角后退者; 2)有角膜病变或者瘢痕者; 3)有眼部炎症者; 4)房角存在新生血管者; 5)伴有严重的系统性疾病者; 6)曾接受过抗青光眼手术或者激光治疗者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Presence of angle closure or angle recession in any quadrant; 2) Individuals with corneal pathologies or scarring; 3) Subjects presenting with ocular inflammation; 4) Cases exhibiting neovascularization of the angle; 5) Patients accompanied by severe systemic diseases; 6) Those with a history of prior anti-glaucoma surgical or laser interventions. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-06-01 00:00:00至 To 2028-05-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-02-01 00:00:00 至 To 2027-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
符合入组条件的开角型青光眼患者将按照随机数字表法分为两组:微脉冲激光小梁成形术治疗组(MLT组)和药物治疗对照组(药物治疗组) |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Open-angle glaucoma patients meeting the inclusion criteria will be divided into two groups according to the random number table method: the treatment group receiving micropulse trabeculoplasty and the control group receiving drug therapy. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究采用纸质病例报告表(CRF)进行数据采集。每名受试者分配唯一受试者编号,所有个人身份信息均以编号替代,以确保隐私。CRF由经过GCP培训的研究者在各访视时间点依据原始医疗记录、实验室检查结果及受试者自报信息完成填写。 纸质CRF由指定的数据管理人员统一归档,存放于上锁的文件柜,仅授权人员可查阅。数据录入前由研究者进行自查,录入后由数据管理人员进行双人核对和逻辑校验,对发现的疑问通过疑问表形式反馈研究者,核实后进行更正并记录修改原因。研究结束后,纸质CRF及相关原始资料将按照伦理委员会及相关法规要求保存至少 5 年。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This study employed paper-based Case Report Forms (CRFs) for data collection. Each subject was assigned a unique subject number, and all personal identification information was replaced with the number to ensure privacy. The CRFs were completed by researchers trained in Good Clinical Practice (GCP) at each visit time point based on the original medical records, laboratory test results, and self-reported information from the subjects. The paper-based CRFs were uniformly archived by designated data managers and stored in locked filing cabinets, accessible only to authorized personnel. Before data entry, researchers conducted self - checks. After data entry, data managers performed double - person verification and logical validation. Any identified queries were fed back to the researchers in the form of query sheets. After verification, corrections were made, and the reasons for the modifications were recorded. After the study was completed, the paper - based CRFs and related original materials would be stored for at least 5 years in accordance with the requirements of the ethics committee and relevant regulations. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |